Case report: Scleromyxedema associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins [PDF]
Frontiers in Immunology, 2023 Scleromyxedema is a rare idiopathic fibromucinous disorder characterized by a generalized papular and sclerodermoid cutaneous eruption. Patients often have praraproteinemia and extracutaneous, even lethal, manifestations.
Shang-shang Wang +2 more
doaj +6 more sources
Indian Journal of Dermatology, Venereology, and Leprology, 2016 Liszaj śluzowaty twardzinowy jest rzadką, postępującą mucynozą skórną, o potencjalnie śmiertelnych konsekwencjach. Rozpoznanie choroby wymaga stwierdzenia 4 cech: grudkowa liszajowata wysypka skórna o typowej lokalizacji; biopsja skóry wykazująca cechy ...
Ying, Yang +3 more
core +6 more sources
Discrete Papular Lichen Myxedematosus and Scleromyxedema with Hypothyroidism: A Report of Two Cases [PDF]
Case Reports in Dermatology, 2019 Scleromyxedema and lichen myxedematosus (LM) are rare disorders that fall along the spectrum of primary cutaneous mucinoses. Scleromyxedema is a systemic form that classically presents with generalized waxy papules, sclerodermoid eruption, and monoclonal
Adele Shenoy +3 more
doaj +4 more sources
Dupilumab improves itch, but not fibrosis, in a patient with scleromyxedema: A case report [PDF]
SAGE Open Medical Case ReportsScleromyxedema is a rare, chronic mucinosis characterized by widespread skin fibrosis and an associated monoclonal gammopathy. Therapeutic options remain limited.
Katya Peri +4 more
doaj +3 more sources
Combination intravenous immunoglobulin, oral prednisone, and methotrexate for managing scleromyxedema: case report and literature discussion [PDF]
Dermatology Reports, 2023 Scleromyxedema (SMX), the generalized and sclerodermic form of lichen myxedematous (LM), is a chronic mucinosis characterized by cutaneous manifestation and several systemic comorbidities.
Gaia Fasano +3 more
doaj +4 more sources
Severe but reversible pulmonary hypertension in scleromyxedema and multiple myeloma: a case report [PDF]
BMC Pulmonary Medicine, 2020 Background Scleromyxedema is a progressive, systemic connective tissue disorder characterized by fibro-mucous skin lesions and increased serum monoclonal immunoglobulin levels.
Mazen Kreidy +3 more
doaj +2 more sources
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2020 SummaryScleromyxedema is a rare, cutaneous deposition disorder from the group of mucinoses, which can affect multiple organs and is virtually always associated with a monoclonal gammopathy. Cutaneous manifestations are usually generalized, 2 to 3 mm sized, dome‐shaped or flat‐topped, waxy, slightly red to skin‐colored papules and sclerodermoid ...
Jochen H O, Hoffmann, Alexander H, Enk
+7 more sources
Severe cutaneous scleromyxedema treated by lenalidomide [PDF]
JEADV Clinical Practice, 2023 Scleromyxedema is a rare clinical variant of primary cutaneous mucinosis. It is defined by a generalized papular and sclerodermoid eruption associated with monoclonal gammopathy. No specific definitive treatment is known and those tried have inconsistent
Théo Brochet +9 more
doaj +2 more sources
Scleromyxedema: clinical diagnosis and autopsy findings [PDF]
Anais Brasileiros de Dermatologia, 2016 Scleromyxedema is a rare chronic cutaneous mucinosis of unknown etiology. It is characterized by papular eruption and scleroderma with microscopic evidence of mucin deposition, fibroblast proliferation, and fibrosis.
Ana Carolina Bulhões Sala +5 more
doaj +4 more sources
Clinical Characteristics and Treatment Outcomes of Scleromyxedema: A 10-Year Retrospective Survey [PDF]
Case Reports in Dermatology, 2022 Scleromyxedema is a rare but important mucinosis disorder of the skin that is presented with dermatological manifestations such as waxy papules, diffuse induration, and nondermatologic involvements like neurological and renal disorders.
Abtin Ansari +6 more
doaj +2 more sources